speb/financial-data huggingface dataset:
ASML.TO income_statement (quarterly, 2024-12-31) — Basic Average Shares: 17870189634.00
ASML.TO income_statement (annual, 2024-12-31) — Basic EPS: 0.42
ASML.TO income_statement (quarterly, 2024-12-31) — Basic EPS: 0.15
ASML.TO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 7004700000.00
ASML.TO cash_flow (annual, 2024-12-31) — Capital Expenditure: -2083100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Capital Stock: 35400000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Capital Stock: 35400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 12735900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 12741300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -2452900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Cash Equivalents: 11229600000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Cash Equivalents: 11229600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Cash Financial: 1506300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Cash Financial: 1506300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -2832100000.00
ASML.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -2609300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 11166200000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Account Payable: 1127600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 625500000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Inventory: -1860900000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -1299000000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 2561300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Payable: 1127600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 1753100000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Receivables: 898800000.00
ASML.TO cash_flow (annual, 2024-12-31) — Change In Working Capital: 2053300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -139900000.00
ASML.TO cash_flow (annual, 2024-12-31) — Changes In Cash: 5724800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Common Stock: 35400000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Common Stock: 35400000.00
ASML.TO cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -2452900000.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Common Stock Dividend Paid: -597800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 18476800000.00
ASML.TO cash_flow (annual, 2024-12-31) — Common Stock Issuance: 124000000.00
ASML.TO cash_flow (annual, 2024-12-31) — Common Stock Payments: -500000000.00
ASML.TO income_statement (annual, 2024-12-31) — Cost Of Revenue: 13770900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 2686600000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Current Accrued Expenses: 2686600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Assets: 30737400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Debt: 1010300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Current Debt: 1010300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 1010300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 1010300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 12570800000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Current Deferred Liabilities: 12570800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 12570800000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Current Deferred Revenue: 12570800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Current Liabilities: 20051400000.00
ASML.TO cash_flow (annual, 2024-12-31) — Deferred Income Tax: -144800000.00
ASML.TO cash_flow (annual, 2024-12-31) — Deferred Tax: -144800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Defined Pension Benefit: 113100000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Defined Pension Benefit: 113100000.00
ASML.TO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 918600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 918600000.00
ASML.TO income_statement (annual, 2024-12-31) — Diluted Average Shares: 17883820595.00
ASML.TO income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 17883820595.00
ASML.TO income_statement (annual, 2024-12-31) — Diluted EPS: 0.42
ASML.TO income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.15
ASML.TO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 7571600000.00
ASML.TO income_statement (annual, 2024-12-31) — EBIT: 9205000000.00
ASML.TO income_statement (annual, 2024-12-31) — EBITDA: 10123600000.00
ASML.TO income_statement (annual, 2024-12-31) — Earnings From Equity Interest Net Of Tax: 209800000.00
ASML.TO cash_flow (annual, 2024-12-31) — Earnings Losses From Equity Investments: 4400000.00
ASML.TO cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 6400000.00
ASML.TO cash_flow (annual, 2024-12-31) — End Cash Position: 12735900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Financial Assets: 0.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Financial Assets: 0.00
ASML.TO cash_flow (annual, 2024-12-31) — Financing Cash Flow: -2832100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Finished Goods: 2019500000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Finished Goods: 2019500000.00
ASML.TO cash_flow (annual, 2024-12-31) — Free Cash Flow: 9083100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 454100000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 454100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Goodwill: 4588600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 5209900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 4477500000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Gross Accounts Receivable: 4477500000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Gross PPE: 11447900000.00
ASML.TO income_statement (annual, 2024-12-31) — Gross Profit: 14492000000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 96500000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Hedging Assets Current: 96500000.00
ASML.TO cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 1098000000.00
ASML.TO income_statement (annual, 2024-12-31) — Interest Expense: 162600000.00
ASML.TO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 162600000.00
ASML.TO income_statement (annual, 2024-12-31) — Interest Income: 182400000.00
ASML.TO income_statement (annual, 2024-12-31) — Interest Income Non Operating: 182400000.00
ASML.TO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 160000000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Inventories Adjustments Allowances: -911500000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Inventories Adjustments Allowances: -911500000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Inventory: 10891500000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Invested Capital: 23164400000.00
ASML.TO cash_flow (annual, 2024-12-31) — Investing Cash Flow: -2609300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Investments And Advances: 903000000.00
ASML.TO cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 124000000.00
ASML.TO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 22500000.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Issuance Of Debt: 22500000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Land And Improvements: 5448400000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 5448400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Leases: 970800000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Leases: 970800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Long Term Debt: 3677300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 3677300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 22500000.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 22500000.00
ASML.TO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -25700000.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: -24100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 903000000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 5025400000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 5025400000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: 0.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -376000000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Income: 7571600000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 7571600000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 7571600000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 7571600000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 7571600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 7571600000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 7571600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -15900000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Interest Income: 19800000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 0.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -3200000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -3200000.00
ASML.TO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 19800000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -526200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Net PPE: 7234000000.00
ASML.TO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -2067200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 13266900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Accounts Receivable: 317200000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Non Current Accounts Receivable: 317200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Accrued Expenses: 459500000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 1940700000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 5924600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 5625400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 1940700000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 299200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Note Receivables: 1456600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Non Current Prepaid Assets: 649400000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Non Current Prepaid Assets: 649400000.00
ASML.TO income_statement (annual, 2024-12-31) — Normalized EBITDA: 10123600000.00
ASML.TO income_statement (annual, 2024-12-31) — Normalized Income: 7571600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Operating Cash Flow: 11166200000.00
ASML.TO cash_flow (annual, 2024-12-31) — Operating Gains Losses: 4400000.00
ASML.TO income_statement (annual, 2024-12-31) — Operating Income: 9022600000.00
ASML.TO income_statement (annual, 2024-12-31) — Operating Revenue: 28262900000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 393283720.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Current Assets: 193400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 454100000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Other Equity Adjustments: 454100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 621300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 28300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Properties: 3300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Receivables: 403200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 5400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Payables: 3783700000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Payables: 3783700000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 6470300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Payables And Accrued Expenses: 6470300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Prepaid Assets: 1371300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 1371300000.00
ASML.TO income_statement (annual, 2024-12-31) — Pretax Income: 9042400000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Properties: 0.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
ASML.TO cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 554700000.00
ASML.TO cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Purchase Of Business: 0.00
ASML.TO cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -15900000.00
ASML.TO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -305200000.00
ASML.TO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -2067200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Raw Materials: 4911200000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Raw Materials: 4911200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Receivables: 5443400000.00
ASML.TO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 13770900000.00
ASML.TO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 918600000.00
ASML.TO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -25700000.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Repayment Of Debt: -24100000.00
ASML.TO cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -500000000.00
ASML.TO income_statement (annual, 2024-12-31) — Research And Development: 4303700000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Retained Earnings: 14414300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Retained Earnings: 14414300000.00
ASML.TO cash_flow (annual, 2024-12-31) — Sale Of Investment: 305200000.00
ASML.TO cash_flow (quarterly, 2024-12-31) — Sale Of Investment: 900000.00
ASML.TO income_statement (annual, 2024-12-31) — Selling General And Administration: 1165700000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Share Issued: 393830692.00
ASML.TO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 172600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 18476800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 13266900000.00
ASML.TO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (annual, 2024-12-31) — Tax Provision: 1680600000.00
ASML.TO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.19
ASML.TO balance_sheet (annual, 2024-12-31) — Taxes Receivable: 562700000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Assets: 48589600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Capitalization: 22154100000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Debt: 4687600000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 18476800000.00
ASML.TO income_statement (annual, 2024-12-31) — Total Expenses: 19240300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 30112800000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 17852200000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 10061400000.00
ASML.TO income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 9022600000.00
ASML.TO income_statement (annual, 2024-12-31) — Total Other Finance Cost: -19800000.00
ASML.TO income_statement (quarterly, 2024-12-31) — Total Other Finance Cost: -6300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Total Tax Payable: 283300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 283300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 546972.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Treasury Shares Number: 546972.00
ASML.TO balance_sheet (annual, 2024-12-31) — Treasury Stock: 476000000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Treasury Stock: 476000000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Work In Process: 4872300000.00
ASML.TO balance_sheet (quarterly, 2024-12-31) — Work In Process: 4872300000.00
ASML.TO balance_sheet (annual, 2024-12-31) — Working Capital: 10686000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — +Operating Expense: 1441800000.00
ASML.TO income_statement (quarterly, 2025-03-31) — +Total Revenue: 7741500000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 4597500000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Asset Impairment Charge: 2100000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 17824753098.00
ASML.TO income_statement (quarterly, 2025-03-31) — Basic EPS: 0.13
ASML.TO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 12735900000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -416500000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 9098400000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 9103600000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -597200000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -3151400000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -415700000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -58600000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -2800800000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -3625700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 17500700000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 38000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -2592600000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 3561800000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Current Assets: 27524400000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 18123900000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: 79100000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Deferred Tax: 79100000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 241300000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 241300000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 17833840405.00
ASML.TO income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.13
ASML.TO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 2355000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — EBIT: 2737900000.00
ASML.TO income_statement (quarterly, 2025-03-31) — EBITDA: 2979200000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Earnings From Equity Interest Net Of Tax: 33000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Earnings Losses From Equity Investments: -34900000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -11800000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — End Cash Position: 9098400000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -3151400000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -475100000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Goodwill: 4588600000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 5180200000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Gross PPE: 7518300000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Gross Profit: 4179700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Inventory: 11024700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 3681000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -415700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 938900000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 38000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 400000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Loans Receivable: 17800000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 3681000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 3681000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 400000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 938900000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -2554600000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Income: 2355000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 2355000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 2355000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 2355000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 2355000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 2355000000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 2355000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -1500000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Interest Income: 49200000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 400000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 400000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 49200000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 800000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Net PPE: 7518300000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -415000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 12320500000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Accounts Receivable: 153400000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Accrued Expenses: 436700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 1861000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 5736500000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 5400600000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 1861000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 335900000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Non Current Note Receivables: 1443400000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 2979200000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Normalized Income: 2355000000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -58600000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -34900000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Operating Income: 2737900000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Operating Revenue: 7741500000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 393200230.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1848600000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 18123900000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 591600000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 859200000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Properties: 7518300000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Receivables: 789000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 5200000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Pretax Income: 2787100000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: 59600000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -1500000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -415000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Receivables: 5547500000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 3561800000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 241300000.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -2592600000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Research And Development: 1161100000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 280700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Share Issued: 393200230.00
ASML.TO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 40000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 17500700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 12320500000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (quarterly, 2025-03-31) — Tax Provision: 465100000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.17
ASML.TO balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 143200000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Assets: 45478800000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 21181700000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Debt: 3681000000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 17500700000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Total Expenses: 5003600000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 27978100000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 17954400000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 9854200000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 2737900000.00
ASML.TO income_statement (quarterly, 2025-03-31) — Total Other Finance Cost: -49200000.00
ASML.TO balance_sheet (quarterly, 2025-03-31) — Working Capital: 9400500000.00
ASML.TO income_statement (quarterly, 2025-06-30) — +Operating Expense: 1465400000.00
ASML.TO income_statement (quarterly, 2025-06-30) — +Total Revenue: 7691700000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 4996900000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: 16500000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 17638463300.00
ASML.TO income_statement (quarterly, 2025-06-30) — Basic EPS: 0.13
ASML.TO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 9098400000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -428900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 7243500000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 7248900000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -714400000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -2163800000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -428000000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 747700000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -1910100000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -1844100000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 17618200000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 36400000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -1485200000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 3562200000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Current Assets: 26710500000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 18616000000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: 38100000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Deferred Tax: 38100000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 254900000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 254900000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 17647550607.00
ASML.TO income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.13
ASML.TO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2290300000.00
ASML.TO income_statement (quarterly, 2025-06-30) — EBIT: 2664100000.00
ASML.TO income_statement (quarterly, 2025-06-30) — EBITDA: 2919000000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Earnings From Equity Interest Net Of Tax: 88800000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Earnings Losses From Equity Investments: -90700000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -10800000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — End Cash Position: 7243500000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -2163800000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 318800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Goodwill: 4588600000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 5154300000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 7661000000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Gross Profit: 4129500000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Inventory: 11575800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 3698900000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -428000000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 1029200000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 36400000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Loans Receivable: 17800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 3698900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 3698900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 1029200000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -1448800000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Income: 2290300000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2290300000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2290300000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2290300000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2290300000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 2290300000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2290300000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -14100000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Interest Income: 24800000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 0.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -600000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -600000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 24800000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: 900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Net PPE: 7661000000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -414800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 12463900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Accounts Receivable: 175100000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Accrued Expenses: 434100000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 1830400000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 4481900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 4187100000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 1830400000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 294800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Non Current Note Receivables: 1444900000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 2919000000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Normalized Income: 2290300000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 747700000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -90700000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Operating Income: 2664100000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Operating Revenue: 7691700000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 388147674.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 1966200000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 18616000000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 565700000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 843700000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Properties: 7661000000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Receivables: 806400000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 5400000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Pretax Income: 2688900000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Provisionand Write Offof Assets: 99700000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -14100000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: 0.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -414800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Receivables: 5919600000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 3562200000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 254900000.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -1485200000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Research And Development: 1166700000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 298700000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Share Issued: 388147674.00
ASML.TO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 49000000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 17618200000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 12463900000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (quarterly, 2025-06-30) — Tax Provision: 487400000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.18
ASML.TO balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 98500000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Assets: 44849100000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 21317100000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Debt: 3698900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 17618200000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Total Expenses: 5027600000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 27230900000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 18138600000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 8614900000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 2664100000.00
ASML.TO income_statement (quarterly, 2025-06-30) — Total Other Finance Cost: -24800000.00
ASML.TO balance_sheet (quarterly, 2025-06-30) — Working Capital: 8094500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — +Operating Expense: 1411900000.00
ASML.TO income_statement (quarterly, 2025-09-30) — +Total Revenue: 7516000000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 5364300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 3100000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 7243500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -315400000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 5126500000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 5128200000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -619600000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -742000000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -1927800000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 559100000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -1903300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Changes In Cash: -2110700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 18993500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 35300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -172200000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 3635700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Current Assets: 25146300000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 19224900000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -55300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Deferred Tax: -55300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 274600000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 274600000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 2124500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — EBIT: 2468400000.00
ASML.TO income_statement (quarterly, 2025-09-30) — EBITDA: 2743000000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Earnings From Equity Interest Net Of Tax: 78900000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: -80800000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -6300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — End Cash Position: 5126500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -742000000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 243700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Goodwill: 4588600000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 5144300000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Gross PPE: 8027200000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Gross Profit: 3880300000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Inventory: 11762800000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 2704700000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1927800000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 2336200000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 35300000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 15000000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Loans Receivable: 190000000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 2704700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 2704700000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: 15000000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -500000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 2336200000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: -1210000000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -136900000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Income: 2124500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 2124500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 2124500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 2124500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 2124500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 2124500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 2124500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -19500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Interest Income: 19400000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 3500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: 14500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 14500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 19400000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -405900000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Net PPE: 8027200000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -295900000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 13849200000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Accrued Expenses: 414500000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 1838600000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 3759500000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 3572300000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 1838600000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 187200000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Non Current Note Receivables: 1686000000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 2743000000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Normalized Income: 2124500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 559100000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -80800000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Operating Income: 2468400000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Operating Revenue: 7516000000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 388147674.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 1575100000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 19224900000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 555700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 918500000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Properties: 8027200000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Receivables: 1032900000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1700000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Pretax Income: 2487800000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Provisionand Write Offof Assets: 138600000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -1210000000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -19500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: 3500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -295900000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Receivables: 6680200000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 3635700000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 274600000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -500000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -172200000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Research And Development: 1108700000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Sale Of Business: -1210000000.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 3500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 303200000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Share Issued: 388147674.00
ASML.TO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 57700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 18993500000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 13849200000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
ASML.TO income_statement (quarterly, 2025-09-30) — Tax Provision: 442200000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.18
ASML.TO balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 93000000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Assets: 45097100000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 21698200000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Debt: 2704700000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 18993500000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Total Expenses: 5047600000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 26103600000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 19950800000.00
ASML.TO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 6878700000.00
ASML.TO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 2468400000.00